Efficacy and Safety of Rifaximin-α in Treating MASLD

计划入组 60 人 · 首次发布于 2026 年 2 月 2 日

Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)

计划入组 30 人 · 首次发布于 2021 年 4 月 22 日

Bactorinol® Nasal Spray With Reduced-Dose Mometasone in Adults With Chronic Rhinosinusitis

计划入组 78 人 · 首次发布于 2026 年 9 月 2 日

Dodekin (Philogen)

anticancer therapy, Philogen/Pfizer

L-19-PDT (Philogen)

Recordati S.p.A.

Italy

RostaQuo S.p.A.

Chiesi Farmaceutici S.p.A.

Italy

Sun Pharma and Philogen Complete Enrollment for Pivotal Phase III FIBROSARC Trial in Soft Tissue Sarcoma

Philogen Resubmits Nidlegy Marketing Application to EMA with Extended Phase III Melanoma Data

Soft Tissue Sarcoma Pipeline Gains Momentum: 70+ Companies Advance 75+ Therapies Across All Development Stages